Clinical Trial Update: Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis [EARLY_Phase 1]

View source ↗

Summary

This early-phase trial evaluating the HPV quadrivalent vaccine for recurrent respiratory papillomatosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Papillomatosis

Drugs mentioned

• Gardasil (human papillomavirus vaccine)

Snippet

Sponsor: University of Missouri-Columbia | Conditions: Recurrent Respiratory Papillomatosis | EARLY_Phase 1 | Status: WITHDRAWN